3 results
The primary goal is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care. This is measured by comparing the proportion of long-term disease flares between the two groups (dose…
The purpose of this study is to investigate how well a new dosage form of tildrakizumab is tolerated when it is administered to healthy volunteers. Tildrakizumab (also known as Ilumetri) is no new compound; it is already available on the market as a…
The main purpose of this study is to assess the impact of arterial stiffness on the response in 24h ambulatory blood pressure reduction following renal sympathetic denervation in patients with primary hypertension with or without diastolic…